SK Biopharm announced it has reached a settlement with Indian generic developer MSN Laboratories regarding a U.S. patent lawsuit over its epilepsy drug, Cenobamate, marketed in the U.S. as Xcopri.
According to SK Biopharm, the two companies agreed to grant MSN the right to launch future generic products under certain conditions related to patent protection. The specific terms of the settlement were not disclosed. This agreement concludes the patent lawsuit pending in the U.S. District Court for the District of Delaware.
The lawsuit was centered on a dispute over follow-on patents rather than the substance patent for Cenobamate. SK Biopharm explained that this settlement allows it to maintain patent protection for Xcopri even after the substance patent expires in 2032. However, the actual launch date of the generic product will depend on regulatory approval from U.S. authorities and undisclosed terms between the two companies.
SK Biopharm is currently involved in patent litigation with two other companies. A company representative stated, "This first settlement helps us solidify our foundation for continued growth and maintain our market position."
Additionally, according to a disclosure regarding a 'single sales and supply contract,' SK Biopharm has signed a supply agreement for Xcopri with its U.S. subsidiary, SK Life Science. The contract is valued at 99.4 billion won, which represents 14.1% of the consolidated revenue of 706.7 billion won for the year 2025.
This large supply contract marks the sixth of its kind this year, bringing the total cumulative contract value to 381.2 billion won.
According to SK Biopharm, the two companies agreed to grant MSN the right to launch future generic products under certain conditions related to patent protection. The specific terms of the settlement were not disclosed. This agreement concludes the patent lawsuit pending in the U.S. District Court for the District of Delaware.
The lawsuit was centered on a dispute over follow-on patents rather than the substance patent for Cenobamate. SK Biopharm explained that this settlement allows it to maintain patent protection for Xcopri even after the substance patent expires in 2032. However, the actual launch date of the generic product will depend on regulatory approval from U.S. authorities and undisclosed terms between the two companies.
SK Biopharm is currently involved in patent litigation with two other companies. A company representative stated, "This first settlement helps us solidify our foundation for continued growth and maintain our market position."
Additionally, according to a disclosure regarding a 'single sales and supply contract,' SK Biopharm has signed a supply agreement for Xcopri with its U.S. subsidiary, SK Life Science. The contract is valued at 99.4 billion won, which represents 14.1% of the consolidated revenue of 706.7 billion won for the year 2025.
This large supply contract marks the sixth of its kind this year, bringing the total cumulative contract value to 381.2 billion won.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.